Literature DB >> 19889100

Orexin receptor subtype activation and locomotor behaviour in the rat.

W K Samson1, S L Bagley, A V Ferguson, M M White.   

Abstract

AIM: Orexin-producing neurones, located primarily in the perifornical region of the lateral hypothalamus, project to a wide spectrum of brain sites where they influence numerous behaviours as well as modulating the neuroendocrine and autonomic responses to stress. While some of the actions of orexin appear to be mediated via the type 1 receptor, some are not, including its action on the release of one stress hormone, prolactin. We describe here the ability of orexin to increase locomotor behaviours and identify the importance of both receptor subtypes in these actions.
METHODS: Rats were tested for their behavioural responses to the central activation of both the type 1 (OX(1)R) and type 2 (OX(2)R) receptor (ICV orexin A), compared to OX(2)R activation using a relatively selective OX(2)R agonist in the absence or presence of an orexin receptor antagonist that possesses highest affinity for OX(1)R.
RESULTS: Increases in locomotor activity were observed, effects which were expressed by not only orexin A, which binds to both the OX(1)R and the OX(2)R receptors, but also by the relatively selective OX(2)R agonist [(Ala(11), Leu(15))-orexin B]. Furthermore, the OX(1)R selective antagonist only partially blocked the action of orexin A on most locomotor behaviours and did not block the actions of [(Ala(11), Leu(15))-orexin B].
CONCLUSION: We conclude that orexin A exerts its effects on locomotor behaviour via both the OX(1)R and OX(2)R and that agonism or antagonism of only one of these receptors for therapeutic purposes (i.e. sleep disorders) would not provide selectivity in terms of associated behavioural side effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889100      PMCID: PMC2860644          DOI: 10.1111/j.1748-1716.2009.02056.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  37 in total

1.  Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord.

Authors:  G J Hervieu; J E Cluderay; D C Harrison; J C Roberts; R A Leslie
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Possible involvement of orexin in the stress reaction in rats.

Authors:  T Ida; K Nakahara; T Murakami; R Hanada; M Nakazato; N Murakami
Journal:  Biochem Biophys Res Commun       Date:  2000-04-02       Impact factor: 3.575

3.  Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting.

Authors:  X Y Lu; D Bagnol; S Burke; H Akil; S J Watson
Journal:  Horm Behav       Date:  2000-06       Impact factor: 3.587

4.  Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats.

Authors:  K A Al-Barazanji; S Wilson; J Baker; D S Jessop; M S Harbuz
Journal:  J Neuroendocrinol       Date:  2001-05       Impact factor: 3.627

5.  Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.

Authors:  N Fujiki; Y Yoshida; B Ripley; K Honda; E Mignot; S Nishino
Journal:  Neuroreport       Date:  2001-04-17       Impact factor: 1.837

6.  Effects of orexins on the hypothalamic-pituitary-adrenal system.

Authors:  M Jászberényi; E Bujdosó; I Pataki; G Telegdy
Journal:  J Neuroendocrinol       Date:  2000-12       Impact factor: 3.627

7.  Sympathetic and cardiovascular actions of orexins in conscious rats.

Authors:  T Shirasaka; M Nakazato; S Matsukura; M Takasaki; H Kannan
Journal:  Am J Physiol       Date:  1999-12

Review 8.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness.

Authors:  J T Willie; R M Chemelli; C M Sinton; M Yanagisawa
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

9.  The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats.

Authors:  S Zhang; L Lin; S Kaur; S Thankachan; C Blanco-Centurion; M Yanagisawa; E Mignot; P J Shiromani
Journal:  Neuroscience       Date:  2007-07-06       Impact factor: 3.590

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

View more
  15 in total

1.  Neurochemical heterogeneity of rats predicted by different measures to be high ethanol consumers.

Authors:  Jessica R Barson; Shawn E Fagan; Guo-Qing Chang; Sarah F Leibowitz
Journal:  Alcohol Clin Exp Res       Date:  2012-06-22       Impact factor: 3.455

2.  Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.

Authors:  Vijayakumar Mavanji; Claudio E Perez-Leighton; Catherine M Kotz; Charles J Billington; Sairam Parthasarathy; Christopher M Sinton; Jennifer A Teske
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

3.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

4.  Methodological considerations for measuring spontaneous physical activity in rodents.

Authors:  Jennifer A Teske; Claudio E Perez-Leighton; Charles J Billington; Catherine M Kotz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-03-05       Impact factor: 3.619

Review 5.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Decreased intake of sucrose solutions in orexin knockout mice.

Authors:  Eiko Matsuo; Ayako Mochizuki; Kiyomi Nakayama; Shiro Nakamura; Takashi Yamamoto; Seiji Shioda; Takeshi Sakurai; Masashi Yanagisawa; Tetsuya Shiuchi; Yasuhiko Minokoshi; Tomio Inoue
Journal:  J Mol Neurosci       Date:  2010-11-18       Impact factor: 3.444

7.  The role of orexin-1 receptors in physiologic responses evoked by microinjection of PgE2 or muscimol into the medial preoptic area.

Authors:  Daniel E Rusyniak; Dmitry V Zaretsky; Maria V Zaretskaia; Joseph A DiMicco
Journal:  Neurosci Lett       Date:  2011-05-17       Impact factor: 3.046

8.  A role for orexin in cytotoxic chemotherapy-induced fatigue.

Authors:  K B Weymann; L J Wood; X Zhu; D L Marks
Journal:  Brain Behav Immun       Date:  2013-11-09       Impact factor: 7.217

9.  The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.

Authors:  Géraldine M Mang; Thomas Dürst; Hugo Bürki; Stefan Imobersteg; Dorothee Abramowski; Edi Schuepbach; Daniel Hoyer; Markus Fendt; Christine E Gee
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

10.  Neuropeptide W increases mean arterial pressure as a result of behavioral arousal.

Authors:  Alicia T Pate; Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-08-07       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.